Ginkgo Bioworks Partners with Deep Origin for Revolutionary Drug Safety Project

Ginkgo Bioworks has announced a partnership with Deep Origin on a 4.5-year initiative funded by the Advanced Research Projects Agency for Health (ARPA-H) under the Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. The collaboration, titled Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation (PREDICTS), is focused on developing an advanced computational platform for evaluating drug safety.

"It's a great opportunity to get to work with the PREDICTS team led by Deep Origin," said Jesse Dill, Senior Director at Ginkgo Bioworks. "It's an extraordinary group with an ambitious vision, and we are excited to generate data characterizing cellular responses to drug treatments to support this effort." George Pilitsis, Director at Ginkgo Bioworks, expressed his enthusiasm, stating, "we are beyond excited and thankful for the opportunity to work with Deep Origin and ARPA-H to push the boundaries of multi-omics data generation and support the vision to transform drug discovery with purpose-built, relevant in vitro models coupled with cutting edge AI."

Dr. Natalie Ma, PhD, Head of Business Development at Deep Origin, highlighted the significance of the collaboration, stating, "Ginkgo's high throughput in vitro platforms mean we can generate data at scale, enabling detailed modeling of a wide array of different cell types in tissues and organs." This partnership reflects Ginkgo's dedication to working with innovative, interdisciplinary teams and showcases its expertise in producing large structured data sets for small molecule drug development.